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A B S T R A C T
Transcatheter aortic valve implantation (TAVI) is an alternative for patients with aortic stenosis at high 
surgical risk and for many of those considered inoperable. Despite its minimally invasive features, 
complications related to the procedure may occur. Coronary obstruction during TAVI is a rare (incidence 
rate of less than 1%) but potentially lethal complication. In Brazil, this complication was found in 0.72% of 
procedures – three of 418 cases from Brazilian Transcatheter Aortic Valve Implantation Registry – with 
an in-hospital mortality rate of 100%. This case report presents prevention and treatment measures for 
coronary occlusion after TAVI. 
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Oclusão coronariana após TAVI: relato de estratégia de segurança
R E S U M O
O implante de valva aórtica transcateter (TAVI) é uma alternativa para pacientes com estenose aórtica 
de alto risco cirúrgico e para muitos daqueles considerados inoperáveis. Apesar de sua característica 
minimamente invasiva, podem ocorrer complicações relacionadas ao procedimento. Obstrução coronária 
durante o TAVI é uma complicação rara, com incidência inferior a 1%, mas potencialmente letal. Em nosso 
país, essa complicação foi encontrada em 0,72% dos procedimentos − 3 de 418 casos do Registro Brasileiro 
de Implante de Bioprótese Aórtica por Cateter − com mortalidade hospitalar de 100%. Apresentamos, neste 
relato de caso, medidas de prevenção e tratamento de oclusão coronária após o TAVI.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Transcatheter aortic valve implantation (TAVI) is the treatment of 
choice for patients with inoperable aortic stenosis, provided that their 
life expectancy is greater than 12 months. TAVI is still an alternative 
to surgery for high-risk patients with a Society of Thoracic Surgeons 
(STS) score of > 8 and < 15.1 Although less invasive, TAVI is characteri-
zed by a substantial rate of serious (fatal and nonfatal) complications, 
especially coronary occlusion (CO). European guidelines consider that 
a patient is at high risk of CO when presenting asymmetric valve cal-
cification, a low coronary ostium, and a small sinus of Valsalva. High 
risk of occlusion is a relative contraindication for TAVI.2
CO during TAVI is a rare event, occurring in less than 1% of 
cases in the registries and in more recent clinical trials. Howe-
ver, it represents a potentially lethal complication.3-6 In the Bra-
zilian Transcatheter Aortic Valve Implantation Registry, CO 
occurred in 3 (0.72%) of 418 procedures, with an in-hospital 
mortality rate of 100%.4,5
Since the first CO report related to TAVI in humans, in 2006,7 the-
re has been an effort by researchers to identify predictors of compli-
cation. However, while the use of TAVI is favored even in those cases 
of higher risk of CO, some measures can be taken to prevent and tre-
at CO, such as those presented in this case report.
0104-1843/© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. This is an open access article under the CC 
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Case report
This report describes the case of a 78-year old female, presenting 
heart failure (functional class III) caused by severe aortic valve ste-
nosis. She had a medical history of coronary artery disease treated 
with percutaneous coronary intervention and implantation of bare-
-metal stents in 2010; permanent pacemaker implantation in 2002; 
hypertension; an asymptomatic 65% right internal carotid lesion; 
systemic lupus erythematosus; chronic hepatitis C; and total left hip 
prosthesis implanted in 2009.
Echocardiography showed tricuspid aortic valve with significant 
calcification, reduced mobility, mild regurgitation, and an area of 
0.55 cm²; maximum and average transvalvular gradients of 70 and 
43 mmHg, respectively; and normal left ventricular (LV) systolic 
function. Coronary angiography showed intra-stent restenosis of 
90% in the right coronary artery (RCA) and of 70% in the left anterior 
descending artery (LADA), as well as segmental stenosis of 90% in 
the left circumflex artery (LCx). Computed tomography (CT) angio-
graphy revealed aortic annulus diameter of 21 mm, sinus of Valsalva 
diameter of 27 mm, sinus of Valsalva/annulus diameter ratio of 1.29, 
RCA ostium height of 8.6 mm, and left coronary artery (LCA) height 
of 10 mm. A left coronary cusp length of 11 mm was observed, while 
the right cusp measured 11.5 mm (Fig. 1). Laboratory results were 
normal: creatinine of 1.1 mg/dL and glomerular filtration rate esti-
mated at 49 mL/min. The estimated risk of death according to the 
STS score was 12.5%.
Given the high risk of aortic valve replacement surgery as well as 
the preference of the patient, the therapeutic decision favored TAVI 
after percutaneous treatment of the coronary lesions.
TAVI was performed in an Artis Zeego (Siemens Healthcare Sec-
tor, Forchheim, Germany) hybrid room, with the patient under ge-
n e r a l  a n e s t h e s i a  a n d  m o n i t o r e d  b y  t r a n s e s o p h a g e a l 
echocardiography. The right femoral arterial access was obtained 
by dissection. The left femoral venous access was percutaneously 
obtained for placement of a temporary pacemaker into the right 
ventricle (RV). The left femoral artery access with a 6 F sheath was 
percutaneously established for the placement of a guide catheter, 
and the right radial artery access with a 6 F sheath was established 
for the placement of a pigtail catheter.
A rotational aortography with 3D reconstruction was obtained 
for identification of the projection with the alignment of the three 
cusps in the same plane (Fig. 2), which was used to release the pros-
thesis. The basal peak-to-peak transvalvular aortic gradient was 43 
mmHg. An Amplatz Super Stiff TM 0.035-inch rigid guide wire (Bos-
ton Scientific Corporation, Natick, USA) was introduced  into the LV 
and, over this guide wire, a 20 mm/40 mm Crystal valvuloplasty 
balloon (Balt, Montmorency, France) was advanced, positioned in 
the aortic valve and inflated to its nominal diameter, under pace-
maker-induced tachycardia. At that moment, an aortography with 
the pigtail catheter positioned into right coronary sinus was perfor-
med. There was no impairment of the right or left coronary flow du-
ring maximum balloon inflation (Fig. 3). Despite this, it was decided 
to adopt an RCA protection strategy. The RCA was catheterized with 
a JR4 6F guide catheter (Medtronic, Minneapolis, USA), and two 
0.014-inch BHW guide wires (Abbott Vascular, Santa Clara, USA) 
were positioned distally into the RCA. A 4.5 mm/12 mm Liberté stent 
(Boston Scientific Co., Natick, USA) was placed distally into the RCA, 
guaranteeing stability to the percutaneous coronary intervention 
system as well as immediate positioning and release into the ostium, 
if necessary. For TAVI, the guide catheter was withdrawn and posi-
tioned just above the sinus of Valsalva (Fig. 4A). Sapien XT 23 mm 
valve (Edwards Lifesciences, California, USA) was advanced over the 
rigid guide wire and positioned in the aortic valve, in order to relea-
se the prosthesis lower (60% ventricular and 40% aortic) than usual 
(60% aortic and 40% ventricular). After angiographic studies for fine-
-tuning the positioning, the prosthesis was released under a heart 
Figure 1. Computed tomography with electrocardiographic synchronization. The dis-
tance from the annulus to the right coronary artery was 8.6 mm and the length of the 
right leaflet was 11.5 mm. Extensive calcification of the aortic valve, particularly in 
non-coronary and right coronary leaflets, is observed.
Figure 2. Rotational angiography of ascending thoracic aorta with 3D reconstruction. 
Working projection identified by aligning the three cusps in the same plane.
Figure 3. Aortography during aortic valve pre-dilation shows the typical contrast of 
right and left coronary arteries.
rate of 180 beats per minute, with full balloon inflation (Fig. 4B). The 
control angiography showed minimum LV reflux and normal con-
trast of both coronary arteries (Fig. 4C). Subsequently, the percuta-
neous coronary intervention system was easily removed. The final 
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manometry showed absence of transvalvular gradient. A control 
transesophageal echocardiogram showed mild periprosthetic aortic 
regurgitation and maximum gradient of 10 mmHg. The patient was 
extubated in-room and transferred to the intensive care unit in a 
clinically and hemodynamically stable condition.
Discussion
CO after TAVI is a rare event, with a mortality rate over 40%. This 
complication can be reasonably anticipated based on the anatomical 
details derived from CT angiography and from aortography during 
valve pre-dilation with balloon. Although the literature is still scar-
ce, there is information indicating risk factors. The main predictors 
are female gender, balloon expandable prosthesis, sinus of Valsalva < 
28 mm, coronary ostium height < 10 mm, and TAVI for treating bio-
prosthesis dysfunction (valve-in-valve). 
Among the mechanisms for CO, the following should be mentio-
ned: (1) ostium covering by a poorly positioned prosthesis, or by a 
well-placed prosthesis, but in a low-lying coronary ostium patient; 
(2) leaflet displacement with gross ostium calcification; (3) calcium 
debris; (4) aortic dissection; (5) leaflet migration towards the ostium 
through avulsion; and (6) displacement of a mobile, greater-length 
leaflet relative to the sinus of Valsalva.8 In the largest registry of co-
ronary obstruction during TAVI, Ribeiro et al.6 analyzed 44 cases 
(0.66%) from 6,688 procedures in 81 centers across four continents. 
The LCA was involved in 88.6% of cases, with most patients showing 
acute signs of severe hypotension, ST-segment changes, and ventri-
cular arrhythmias. In three patients (6.8%), death occurred within 
minutes, not allowing any coronary artery bypass graft procedure. 
Angioplasty was performed in 75% of cases, with an 81.8% success 
rate. The overall 30-day and 12-month mortality rates were 40.9% 
and 45.5%, respectively. The mortality of patients with successful 
angioplasty was 22.2%, and 100% in those whose angioplasty failed. 
For those patients who opted for coronary artery bypass graft (14%), 
mortality was 50%. Circulatory support was required in 36% of pa-
tients. There were no cases of stent thrombosis or need for coronary 
artery bypass graft of the target lesion in a mean follow-up of 12 
months.
In the same study by Ribeiro et al.,6 the following predictors were 
identified for coronary obstruction: female gender, valve-in-valve 
procedure, balloon expandable prosthesis implantation (0.81% vs. 
0.31% occurrence with auto-expandable prostheses), sinus of Valsal-
va diameter < 30 mm, and left coronary ostium height < 12 mm. Re-
garding LCA ostium height, the mean was 11 mm among those 
patients with post-TAVI coronary obstruction, and 13 mm in those 
without this complication. In women, the mean LCA ostium height 
was even lower (10 mm); and in 96% of those with obstruction, their 
LCA ostium height was < 12 mm. LCA obstruction was uncommon 
(only 11% of cases), a fact probably related to its often higher origin; 
however, it was not possible to estimate a safe cut-off point due to 
the small number of cases.
Other possible predictors include coronary obstruction observed 
during aortic balloon valvuloplasty with simultaneous aortogra-
phy,9 and a leaflet length/curve length of sinus of Valsalva ratio > 1, 
as shown by Okuyama et al.8
Although the present report does not describe a case of coro-
nary obstruction treated by the safety technique utilized, the risk 
of occurrence of this complication justifies the action taken, as 
the patient was a female with RCA ostium height < 10 mm and 
with sinus of Valsalva diameter of 27 mm. A valve pre-dilation 
balloon with 1:1 ratio for the valve annulus was used to assess 
coronary f low during inflation. There was no right or left coro-
nary flow impairment. Aortography performed during pre-dila-
tion with a balloon with a smaller diameter than that of the 
annulus may underestimate the risk of CO, because the leaflets 
are not fully displaced, as occurs after implantation of the pros-
thesis. The two 0.014-inch Extra Support guide wires and the 
stent distally positioned into RCA maintained perfect stability of 
the system, with guide catheter retrocession during positioning 
and release of the prosthesis. One of the recommendations, based 
on the expert opinion of the management of these high risk pa-
tients for occurrence of CO in TAVI, is to leave a percutaneous co-
ronary intervention guide wire into the coronary artery;6,9 
however, the authors had no access to any publication with a re-
commendation of distal stent placement into the coronary artery 
of interest, except for valve-in-valve.10 This maneuver provides a 
rapid reversal of any possible CO. Another measure was to release 
the prosthesis placed in a lower position (60% ventricular and 40% 
aortic) than usual in order to avoid covering the coronary ostia 
with bioprosthesis' metallic struts. 
Figure 4. (A) On the left, demonstration of the therapeutic armamentarium: balloon expandable prosthesis release system into descending aorta (1) over Amplatz SuperStiffTM 
guide wire with its end into the left ventricle (2); a temporary pacemaker electrode into the right ventricle (3); pigtail catheter into the right coronary sinus (4); JR 6 F guide 
catheter (5) above the sinus of Valsalva; two 0.014-inch Extra Support guide wires and coronary stent placed distally into the right coronary artery (6); permanent pacemaker 
electrodes into the right ventricle and atrium (7 and 8) (B). Release of balloon expandable aortic valve prosthesis, with percutaneous coronary intervention system positioned 
into the right coronary artery. (C) Control aortography showing right and left coronary artery patency and minimum aortic regurgitation.
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The authors also believe that, given the need to start the circula-
tory support, the placement and positioning of 0.035-inch teflonized 
guide wires into the superior vena cava and into the contralateral 
femoral artery are justifiable in patients at higher risk of hemodyna-
mic instability. Finally, the choice of repositionable or recapturable 
prostheses can provide greater safety for these patients.
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